Consensus 69c. Lowers FY24 revenue view to $1.23B-$1.27B from $1.3B-$1.32B, consensus $1.3B. “Since becoming a public company, our guidance has always been based on the utilization we are currently seeing, which informed our previous view of 2024. As utilization is now slightly lower than the record levels we saw in 2023, we are revising our guidance for the year,” said Anevski.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGNY:
- Progyny, Inc. Announces Details for Its First Quarter 2024 Results Report
- Progyny and Fertility Matters Canada Recognize Canadian Fertility Awareness Week to Advocate for Expanded Access to Family Building Care
- Progyny and RESOLVE to Honor National Infertility Awareness Week® with Events Spanning Coast to Coast
- Progyny, Inc. to Present at KeyBanc Life Sciences & MedTech Investor Forum
- Progyny, Inc. to Present at Barclays 26th Annual Global Healthcare Conference